About MaSTherCell
MaSTherCell is a Healthcare company based in Charleroi (Belgium) founded in 2011, and was acquired by Catalent in February 2020. Services for cell therapy development and manufacturing are provided. MaSTherCell has raised $17.37 million across 2 funding rounds from investors including Catalent, Hearst and Orgenesis. The company has 329 employees. MaSTherCell offers products and services including Cosmetic Treatments and Consultations. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Cell and Gene Therapy. Its legal entity is Catalent Gosselies.
Company details
MaSTherCell (Manufacturing Synergies for Therapeutic Cells) is a Belgian Contract Development and Manufacturing Organisation, offering its services for the development of cell therapy products. Companys services include process and assay development, GMP manufacturing and quality control services of cell therapy products. The companys services can be availed right from Phase - I to commercialization of the product. Their facilities are authorized by Belgian Drug Agency (AFMPS). The company claims that their quality control services are performed in accordance with European and US pharmacopeia, FDA and EMA. MaSTherCell was acquired by Orgenesis (a company offering cellular therapy and regenerative medicines for the treatment of Type 1 Diabetes) in March 2015. In August 2016, the company was selected by Adaptimmune as a supplier of cell therapy products for use in Adaptimmunes clinical trials.
- Headquarters Charleroi, Belgium
- Employees 329
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website masthercell.com
- Social LinkedIn X
- Acquired by Catalent (Feb 2020)
- Legal Name Catalent Gosselies
- Annual Revenue$65.41 M (USD)44as on Jun 30, 2022
- Net Profit-$10.38 M (USD)-38as on Jun 30, 2022
- EBITDA-$10.28 M (USD)-37as on Jun 30, 2022
- Total Equity Funding$17.37M (USD)
in 2 rounds
- Latest Funding Round$11.8M (USD), Series A
Jun 2018
- InvestorsCatalent
& 6 more
- Employee Count329
- Acquired by
Products & Services of MaSTherCell
MaSTherCell offers a comprehensive portfolio of products and services, including Cosmetic Treatments and Consultations.
Delivers non-surgical cosmetic services using evidence-based protocols for client satisfaction.
Provides personalized advice and treatment planning for cosmetic medical needs.
Funding Insights of MaSTherCell
MaSTherCell has successfully raised a total of $17.37M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.8 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.37M
- Total Rounds 2
- Last Round Series A — $11.8M
- First Round $5.57M
(Jun 2011)
- Investors Count 5
All 2 funding rounds of MaSTherCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $11.8M | Series A | – | Great Point Partners | |
| Jun 2011 | $5.57M | Seed | – | – |
7 investors in total: 7 institutional.
Investors in MaSTherCell
MaSTherCell has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Catalent, Hearst and Orgenesis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Early to late-stage tech investments are made globally by REV. | rev.vc | London, United Kingdom | ||
VC & PE fund | sambrinvest.be | Charleroi, Belgium | ||
Media conglomerate | 1887 | hearst.com | New York, United States | |
Business development services for medical device manufacturing are provided. | 2006 | biowin.org | Charleroi, Belgium | |
Cell and gene therapies for multiple disorders are developed. | 2008 | orgenesis.com | Germantown, United States | |
CDMO offering drug and biologics development services | 2007 | catalent.com | Somerset, United States |
Investor details for MaSTherCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of MaSTherCell
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Masthercell
Complete news archive for MaSTherCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MaSTherCell
MaSTherCell was founded in 2011.
MaSTherCell is headquartered in Charleroi, Belgium. It is registered at Charleroi, Walloon Region, Belgium.
MaSTherCell is a funded company, having raised a total of $17.37M across 2 funding rounds to date. The company's 1st funding round was a Seed of $5.57M, raised on Jun 2011.
MaSTherCell has 329 employees.
Annual revenue of MaSTherCell is $65.41M as on Jun 30, 2022.
MaSTherCell (Manufacturing Synergies for Therapeutic Cells) is a Belgian Contract Development and Manufacturing Organisation, offering its services for the development of cell therapy products. Companys services include process and assay development, GMP manufacturing and quality control services of cell therapy products. The companys services can be availed right from Phase - I to commercialization of the product. Their facilities are authorized by Belgian Drug Agency (AFMPS). The company claims that their quality control services are performed in accordance with European and US pharmacopeia, FDA and EMA. MaSTherCell was acquired by Orgenesis (a company offering cellular therapy and regenerative medicines for the treatment of Type 1 Diabetes) in March 2015. In August 2016, the company was selected by Adaptimmune as a supplier of cell therapy products for use in Adaptimmunes clinical trials.
MaSTherCell offers Cosmetic Treatments and Consultations.
MaSTherCell has 7 investors. Key investors include Catalent, Hearst, Orgenesis, Biowin, and Great Point Partners.
MaSTherCell operates through Catalent Gosselies.
Yes. MaSTherCell was acquired by Catalent in February 2020.